SGLT2 Inhibitors: Basic Training Quiz

The sodium glucose cotransporter-2 inhibitors are the newest diabetes drugs available. Have you got the basic concepts under your belt? Try these 6 questions and find out.


The ADA recommends GLP-1 agonists as second-line therapy against type 2 diabetes. What makes this class unique in its impact on hyperglycemia?

Metabolic disorders in patients with diabetes place them at particularly high risk for CV morbidity. Find insights on Dx and Tx in these slides.

GI side effects compel many patients to stop GLP-1 agonist therapy. A new study identifies important risk factors to consider before prescribing.

Incretin-based therapies have shown beneficial effects on the cardiovascular system, providing impetus for this recent study.

Try this mid-week Q&A on 2 essential properties of the sodium glucose cotransporter 2 (SGLT2) inhibitors.

What do you get when you combine an SGLT2 inhibitor and a GLP-1 receptor agonist into therapy for 1 diabetes patient?

Our endo blogger has her theories about why doing what you thought you loved just seems to sap your soul.


Subscribe to Diabetes on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.